Elli Lilly's Weight Loss Drug To Be Covered In Medicare Insurance In US For THIS Treatment - All You Need To Know
(MENAFN- Live Mint) Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the blockbuster weight-loss treatment.
The Wednesday statement from the Centers for Medicare & Medicaid Services comes after Zepbound in December became the first drug approved in the U.S. for sleep apnea, strengthening its case for coverage as Medicare cannot cover obesity drugs unless they are approved for a secondary use by the Food and Drug Administration .
Commercial insurers and employers were previously hesitant to cover the drug due to its high cost of over $1,000 a month.
Also Read | Eli Lilly and Novo Nordisk's obesity moat just got stronger Insurers can still choose not to cover Zepbound, despite the CMS's guidance.
Last year, rival Novo Nordisk 's obesity drug Wegovy also gained Medicare coverage to reduce the risk of heart attacks and strokes.
Lilly and Novo are testing their blockbuster obesity drugs for a range of conditions as they race to demonstrate that the treatments have other health benefits.
The Biden administration proposed to expand the coverage of drugs to treat obesity in November last year. If President-elect Donald Trump' s incoming administration backs the move, it would be effective from 2026.
About 65 million people are enrolled in Medicare plans, intended for people aged 65 and older or those who are disabled.
Sleep apnea, which affects around one billion people globally, causes patients to stop breathing briefly while sleeping, disturbing the sleep cycle and causing long-term complications such as heart conditions.
Common treatments recommended for the condition include CPAP (continuous positive airway pressure) machines, surgery, as well as losing weight.
Zepbound and Lilly's other blockbuster diabetes drug, Mounjaro, belong to a class of drugs called GLP-1 agonists. Analysts have forecast the market for GLP-1 drugs could reach at least $150 billion a year by the early 2030s
MENAFN08012025007365015876ID1109070414
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.